RU2016142819A - Твердая композиция, содержащая аморфный софосбувир - Google Patents

Твердая композиция, содержащая аморфный софосбувир Download PDF

Info

Publication number
RU2016142819A
RU2016142819A RU2016142819A RU2016142819A RU2016142819A RU 2016142819 A RU2016142819 A RU 2016142819A RU 2016142819 A RU2016142819 A RU 2016142819A RU 2016142819 A RU2016142819 A RU 2016142819A RU 2016142819 A RU2016142819 A RU 2016142819A
Authority
RU
Russia
Prior art keywords
sofosbuvir
weight
chemical compound
solid composition
matrix chemical
Prior art date
Application number
RU2016142819A
Other languages
English (en)
Russian (ru)
Other versions
RU2016142819A3 (cg-RX-API-DMAC10.html
Inventor
Нольвенн МАРТИН
Original Assignee
Сандоз Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сандоз Аг filed Critical Сандоз Аг
Publication of RU2016142819A3 publication Critical patent/RU2016142819A3/ru
Publication of RU2016142819A publication Critical patent/RU2016142819A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/222—Amides of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2016142819A 2014-04-03 2015-04-02 Твердая композиция, содержащая аморфный софосбувир RU2016142819A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14163434.5 2014-04-03
EP14163434 2014-04-03
PCT/EP2015/057411 WO2015150561A2 (en) 2014-04-03 2015-04-02 Solid composition comprising amorphous sofosbuvir

Publications (2)

Publication Number Publication Date
RU2016142819A3 RU2016142819A3 (cg-RX-API-DMAC10.html) 2018-05-10
RU2016142819A true RU2016142819A (ru) 2018-05-10

Family

ID=50397065

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016142819A RU2016142819A (ru) 2014-04-03 2015-04-02 Твердая композиция, содержащая аморфный софосбувир

Country Status (10)

Country Link
US (2) US10493089B2 (cg-RX-API-DMAC10.html)
EP (1) EP3125868A2 (cg-RX-API-DMAC10.html)
JP (1) JP2017512811A (cg-RX-API-DMAC10.html)
KR (1) KR20160142342A (cg-RX-API-DMAC10.html)
CN (1) CN106163529A (cg-RX-API-DMAC10.html)
AU (1) AU2015239018A1 (cg-RX-API-DMAC10.html)
CA (1) CA2943574A1 (cg-RX-API-DMAC10.html)
MX (2) MX2016012934A (cg-RX-API-DMAC10.html)
RU (1) RU2016142819A (cg-RX-API-DMAC10.html)
WO (1) WO2015150561A2 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3154526T1 (sl) 2014-06-13 2019-08-30 Ratiopharm Gmbh Trdne oblike sofosbuvira
WO2016038542A2 (en) * 2014-09-10 2016-03-17 Mylan Laboratories Limited Polymorphic forms of sofosbuvir
CZ2015443A3 (cs) * 2015-06-26 2017-01-04 Zentiva, K.S. Farmaceutická formulace sofosbuviru
EP3359199A1 (en) * 2015-10-07 2018-08-15 Sandoz AG Solid pharmaceutical composition comprising amorphous sofosbuvir
CZ2016257A3 (cs) * 2016-05-05 2017-11-15 Zentiva, K.S. Amorfní forma sofosbuviru, způsob její přípravy a její stabilizace
CN106083963A (zh) * 2016-06-08 2016-11-09 上海现代制药海门有限公司 一种索非布韦晶型6的制备方法
MX2019001771A (es) * 2016-08-12 2019-11-18 Sandoz Ag Composición farmacéutica sólida que comprende el sofosbuvir amorfo.
CZ2016553A3 (cs) 2016-09-09 2018-03-21 Zentiva, K.S. Pevná farmaceutická dávková forma obsahující sofosbuvir
WO2018078536A1 (en) 2016-10-26 2018-05-03 Lupin Limited Stable solid dispersion of sofosbuvir and process for preparation thereof
CN108210509A (zh) * 2016-12-13 2018-06-29 南京圣和药业股份有限公司 新的核苷氨基磷酸脂化合物的组合物及其制备方法
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
WO2019134971A1 (en) * 2018-01-04 2019-07-11 Sandoz Ag Encapsulated particles comprising a pharmaceutically active ingredient
WO2020071539A1 (ja) 2018-10-05 2020-04-09 富士化学工業株式会社 多孔性シリカ粒子組成物
CN111040010A (zh) * 2019-12-23 2020-04-21 上海红蓝医药科技有限公司 一种索非布韦中间体的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500358A (ja) * 1999-12-08 2004-01-08 ファルマシア コーポレイション バイオアベイラビリティーが増加した固体状態のセレコキシブ
CN1200262C (zh) 2003-01-10 2005-05-04 清华大学 测量粉末吸附气体量的方法和设备
WO2010017965A2 (en) 2008-08-11 2010-02-18 Merck Serono S.A. SOLID LIPID MICROCAPSULES CONTAINING hGH
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
AP2012006535A0 (en) 2010-03-31 2012-10-31 Gilead Pharmasset Llc Stereoselective synthesis of phosphorous containing actives
JP5781706B2 (ja) * 2011-12-29 2015-09-24 アッヴィ・アイルランド・アンリミテッド・カンパニー Hcv阻害剤を含む固体組成物
MY168529A (en) * 2011-12-30 2018-11-12 Chevron Usa Inc Process, method, and system for removing heavy metals from fluids
EA201690473A1 (ru) * 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений

Also Published As

Publication number Publication date
MX2019009842A (es) 2019-10-22
MX2016012934A (es) 2016-12-07
RU2016142819A3 (cg-RX-API-DMAC10.html) 2018-05-10
WO2015150561A3 (en) 2016-01-28
CN106163529A (zh) 2016-11-23
AU2015239018A1 (en) 2016-10-13
US20170100422A1 (en) 2017-04-13
US10493089B2 (en) 2019-12-03
KR20160142342A (ko) 2016-12-12
EP3125868A2 (en) 2017-02-08
US20190381085A1 (en) 2019-12-19
JP2017512811A (ja) 2017-05-25
CA2943574A1 (en) 2015-10-08
WO2015150561A2 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
JP2017512811A5 (cg-RX-API-DMAC10.html)
RU2019138248A (ru) Фармацевтическая композиция для перорального введения, содержащая энзалутамид
CA2943574A1 (en) Solid composition comprising amorphous sofosbuvir
WO2014195966A2 (en) Amorphous form of canagliflozin and process for preparing thereof
JP2009235100A5 (cg-RX-API-DMAC10.html)
JP2014237658A5 (cg-RX-API-DMAC10.html)
JP2017532374A5 (cg-RX-API-DMAC10.html)
JP2019520321A5 (cg-RX-API-DMAC10.html)
JP2014518226A5 (cg-RX-API-DMAC10.html)
JP2021105043A (ja) 非溶媒和物結晶及びその製造方法、並びに応用
JP2012502902A (ja) アデホビルジピボキシルの安定化した固体分散体及びその製造方法
CN108136033A (zh) 包含无定形索非布韦的固体药物组合物
US9089834B2 (en) Brominated sorbents for removing mercury from emissions produced during fuel combustion
JP7262321B2 (ja) アルデヒド捕捉剤
HRP20161691T1 (hr) Derivati ariletinila
JP2012505194A (ja) 有機溶媒を使用したモキシフロキサシンの湿式造粒法
EP3254674A1 (en) Pharmaceutical compositions of betrixaban maleate
RU2012121183A (ru) Фармацевтическая композиция для перорального введения
FI2648701T3 (fi) Hyvin stabiileja adefovirdipivoksiilin koostumuksia
RU2008130873A (ru) Комбинированный состав, включающий амлодипина камсилат и симвастатин и способ его приготовления
JP2016505026A5 (cg-RX-API-DMAC10.html)
RU2013102823A (ru) Способ получения гибких композиционных сорбционно-активных материалов
RU2020102280A (ru) Фармацевтическая композиция и способ ее получения
JP2013543881A5 (cg-RX-API-DMAC10.html)
ATE521337T1 (de) Verfahren zur herstellung einer pharmazeutischen co-kristall-zusammensetzung

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20191212